ID   COLO 849
AC   CVCL_2002
SY   COLO-849; Colo 849; COLO #849; COLO849; Colorado 849
DR   CLO; CLO_0002578
DR   EFO; EFO_0006379
DR   CLDB; cl872
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03473234
DR   cancercelllines; CVCL_2002
DR   Cell_Model_Passport; SIDM01870
DR   Cosmic; 888062
DR   DepMap; ACH-001045
DR   DSMZ; ACC-216
DR   DSMZCellDive; ACC-216
DR   EGA; EGAS00001000610
DR   GEO; GSM886954
DR   GEO; GSM888022
DR   IARC_TP53; 21247
DR   LINCS_LDP; LCL-1245
DR   PharmacoDB; COLO849_239_2019
DR   Progenetix; CVCL_2002
DR   Wikidata; Q54814168
RX   PubMed=7780963;
RX   PubMed=8402545;
RX   PubMed=11668190;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: ~50-60 hours (DSMZ=ACC-216).
CC   HLA typing: A*01:01,03:01; B*08:01,40:02; C*03:04,07:01 (PubMed=26589293).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.07%; East Asian, North=2.02%; East Asian, South=0%; South Asian=0%; European, North=73.1%; European, South=24.82% (PubMed=30894373).
CC   Derived from site: Metastatic; Right axillary lymph node; UBERON=UBERON_0001097.
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 13
ST   D18S51: 15
ST   D19S433: 14,15
ST   D21S11: 27,29
ST   D2S1338: 18,26
ST   D3S1358: 16,18
ST   D5S818: 11
ST   D7S820: 8,10
ST   D8S1179: 13,14 (PubMed=25877200)
ST   D8S1179: 13,16 (DSMZ)
ST   FGA: 21,25
ST   Penta D: 9,14
ST   Penta E: 7,12
ST   TH01: 10
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1137 ! COLO 829
OI   CVCL_1999 ! COLO 829BL
OI   CVCL_L503 ! COLO 831
OI   CVCL_2000 ! COLO 832
OI   CVCL_L504 ! COLO 833
OI   CVCL_L505 ! COLO 834
OI   CVCL_L506 ! COLO 835
OI   CVCL_L507 ! COLO 838
OI   CVCL_2001 ! COLO 839
OI   CVCL_L508 ! COLO 845
OI   CVCL_L509 ! COLO 848
OI   CVCL_2003 ! COLO 853
OI   CVCL_2004 ! COLO 857
OI   CVCL_2005 ! COLO 858
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 31
//
RX   PubMed=7780963;
RA   Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A.,
RA   Toso R.J., Herlyn M., Bennett D.C.;
RT   "Protein B61 as a new growth factor: expression of B61 and
RT   up-regulation of its receptor epithelial cell kinase during melanoma
RT   progression.";
RL   Cancer Res. 55:2528-2532(1995).
//
RX   PubMed=8402545; DOI=10.1016/0165-4608(93)90083-X;
RA   Morse H.G., Moore G.E.;
RT   "Cytogenetic homogeneity in eight independent sites in a case of
RT   malignant melanoma.";
RL   Cancer Genet. Cytogenet. 69:108-112(1993).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//